Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14488147 | 0.98 | SIGMAR1 (0.35) | SIGMAR1TMEM97KDM4EALDH1A1 | |
| SCHEMBL9801669 | 0.85 | SIGMAR1 (0.35) | SIGMAR1 | |
| SCHEMBL7984593 | 0.83 | SIGMAR1 (0.40) | SIGMAR1TMEM97KDM4EALDH1A1 | |
| SCHEMBL7380009 | 0.83 | SIGMAR1 (0.35) | SIGMAR1TMEM97KDM4EALDH1A1 | |
| SCHEMBL9801964 | 0.82 | SIGMAR1 (0.40) | SIGMAR1TMEM97KDM4EALDH1A1 | |
| SCHEMBL9801178 | 0.82 | ALOX15 (0.43) | SIGMAR1 | |
| SCHEMBL9870178 | 0.81 | SIGMAR1 (0.33) | SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL9801615 | 0.79 | SIGMAR1 (0.44) | SIGMAR1TMEM97ALDH1A1 | |
| SCHEMBL9801645 | 0.79 | FNTA (0.32) | SIGMAR1 | |
| SCHEMBL9801740 | 0.79 | KEAP1 (0.36) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4487845-A | COORDINATION, POLYMERIZATION CATALYST FOR OLEFINS | STAUFFER CHEMICAL COMPANY (US) | 1984-12-11 | — | — | US | claimed |
| US-9611245-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-04-04 | — | — | US | disclosed |
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2016-08-18 | — | — | US | disclosed |
| CN-104730891-A | Cleaning blade, cleaning device, and image forming apparatus | FUJI XEROX CO LTD | 2015-06-24 | — | — | CN | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | NR1D1, NR1I3, BCOR | SIGMAR1 353/4885TMEM97 1373/4885KDM4E 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.